Prognostic value of cell-free DNA in patients with oropharyngeal cancers.

Julia Beck, Margret Rave-Fraenk, et al. Prognostic value of cell-free DNA in patients with oropharyngeal cancers.J Clin Oncol 34, 2016 (suppl; abstr e17511).

Tumor derived plasma cell-free DNA (TcfDNA) is described as biomarker to monitor tumor burden in cancer. Large somatic genome aberrations are hallmarks of malignancies and detectable in cfDNA. However, levels of TcfDNA are variable according to cancer types. We obtained copy-number instability (CNI) scores of cfDNA in treatment-naïve head and neck cancers before and after therapy.

By | November 2nd, 2016|Other publications|0 Comments

Combining Genome Change Index (GCI) and liquid biopsy to predict and monitor therapeutic responses.

Ekkehard Schütz, Julia Beck, Donald Peter Braun, Howard B. Urnovitz , et al. Combining Genome Change Index (GCI) and liquid biopsy to predict and monitor therapeutic responses.J Clin Oncol 33, 2015 (suppl; abstr e22020) .

Genomic instability of tumor cells has been associated with a poor prognosis. However, impaired DNA repair pathways leading to genomic instability are also described to increase tumor sensitivity to DNA damaging agents. A comprehensive Genomic Change Index (GCI) as an indicator of defective DNA repair is proposed as a potential predictor of cytotoxic chemotherapy (chemo) response.

By | November 2nd, 2016|Other publications|0 Comments